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Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors 
derived from the chromaffin tissue. Diagnosis of these tumors is extremely important as 
they are linked to the hypertension syndrome with great cardiovascular morbidity and 
mortality. A great majority of PCCs and PGLs are sporadic and benign tumors; however, 
the classic idea of 10% exception of these features is changing. The description of new 
genes linked to familial forms of PCC/PGLs, such as succinate dehydrogenase (SDH) 
complex subunits, KIF1Bβ, EGLN1, TMEM127, and MAX, added to the well-known PCC 
familial syndrome (MEN2, VHL, and neurofibromatosis type 1) presents new challenges 
for diagnosis. In this review, we discuss the diversity of clinical and genetic approaches 
to this syndrome as well the diverse criteria that should guide genetic investigation.
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introduction
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors derived from 
the chromaffin tissue of the adrenal medulla or from extra-adrenal sympathetic and parasympathetic 
paraganglia. Parasympathetic PGLs are mostly non-secreting, whereas sympathetic PGLs generally 
produce catecholamine (1, 2).
The diagnosis of these neoplasias is extremely important, as they are associated with hyperten-
sion syndrome and great cardiovascular morbidity and mortality. The prevalence of PCC/PGLs in 
general hypertensive population is on average 0.1–0.6% and even higher in children (1.7%), with 
5% of incidentally discovered adrenal mass (1, 3, 4). However, with modern imaging, 20–30% 
of these tumors are incidentally discovered (5). Therefore, high suspicion is necessary to avoid 
misdiagnosis.
Clinical Diagnosis Based on Genetic Aspects
The American Endocrine Society guidelines advocate that it is important to be aware of the main 
clinical features for proper diagnosis of PCC/PGLs (5). The clinical presentation of these tumors 
can overlap with other clinical conditions with non-specific symptoms, such as tachycardia, dia-
phoresis, pallor, anxiety, headaches, panic attacks, and sensation of sudden death. Hypertension 
may or may not be present; as previously described by an Italian group where 21% of patients 
with PCC were normotensive, and it can appear as a sustained sign or during paroxysm (6). In 
humans, blood pressure depends on many factors including the sympathetic nervous system and 
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the renin–angiotensin–aldosterone system among other factors. 
In patients with PCC, however, the behavior of hypertension 
depends also on the circulating catecholamine levels and even-
tually by other cardiovascular active substances secreted by the 
tumor. Moreover, production of vasodilator substances, such as 
dopamine or prostaglandins, downregulation of alpha-1 adren-
ergic receptors, and the presence of hypovolemia can contribute 
to this variability. Norepinephrine (NE)-secreting tumors usually 
cause sustained hypertension, while tumors that produce epi-
nephrine (E) co-secreted with NE commonly result in episodic 
hypertension. Pure E-secreting tumors can present hypotension 
instead of high pressure as a symptom (7). Large cystic tumors are 
often asymptomatic because part of the catecholamine produced 
is metabolized inside the tumors before being released into cir-
culation (8).
The heterogeneity of PCCs/PGLs clinical presentation explains 
the reason why this disease frequently is not considered as a pos-
sible diagnose condition, though can provoke a life-threatening 
crisis. At that point, any patient with the clinical manifestations 
cited before should be included as a case suspicion and must be 
properly screened for PCCs. These tumors occur in any age, but 
predominantly between 40 and 50 years, with approximately equal 
sex distribution (9, 10). However, the age of appearance can change 
in hereditary tumors, and they often occur at an earlier age. A 
great majority of PCCs and PGLs are sporadic and benign tumors; 
however, the classic idea of the traditional 10% rule for these 
features is changing. Occurrence of hereditary-associated tumors 
has increased to 30%. Also, diagnosis of several syndromes, such as 
multiple endocrine neoplasia type 2 (MEN2), von Hippel–Lindau 
disease (VHL), and neurofibromatosis type 1, has increased. 
Recently, additional mutations in the succinate dehydrogenase 
(SDH) complex subunits, SDHA, SDHB, SDHC, SDHD, and 
SDHFA2, related to familial PCC–PGL and novel susceptibility 
genes, such as KIF1Bβ, EGLN1, TMEM127, and MAX, have led 
to the diagnosis of new phenotypes (11, 12). Patient criteria, such 
as younger age, positive familial history for PCC/PGL, tumor 
bilaterally/multifocal, and recurrence or malignancy, could guide 
selection of patients who may be under greater risk of genetic 
abnormality (Figure 1). Genetic tests are expensive, and therefore, 
the knowledge of links between specific clinical and biochemical 
phenotype and PCC/PGLs-related genes and syndromes could 
reduce the cost of genetic screening significantly. This review aims 
to provide an overview of the genetic susceptibility of these tumors, 
clarifying and reinforcing the importance of their diagnosis.
Genes and Syndromes Related to PCC/PGL
Multiple endocrine Neoplasia
Multiple endocrine neoplasia type 2 is described by medullary 
thyroid carcinomas (MTC) in association with PCC. This syn-
drome has three clinical variants: MEN2A (55% of cases), familial 
medullary thyroid carcinoma (FMTC – 35–40%), and MEN2B 
(5–10%) (13). The disease is caused by the germ-line mutation 
of the proto-oncogene, RET (rearranged during transfection). 
This 21-exon proto-oncogene is located on chromosome 10 and 
encodes a receptor tyrosine kinase that works in conjunction with 
glial-derived neurotrophic factor family ligands. The interaction 
FiGURe 1 | Clinical aspects to guide the screening for genetic 
abnormality include younger age of tumor appearance, positive 
family history, bilaterally multifocal tumors, and recurrence or 
malignancy.
of these ligands results in the dimerization of the RET receptor, 
auto-phosphorylation of tyrosine residues, and finally cell growth 
and survival mediated by the mitogen-activated protein kinase 
intracellular signaling cascade. One germ-line activating muta-
tion of this gene, generally missense and located in exons 10, 
11, 13, 14, 15, 16, has been implicated in this syndrome (14, 15). 
MEN2A is also associated with hyperparathyroidism in 20–30% 
of the patients, unlike MEN2B, in which this feature is absent 
and marfanoid habitus calls attention. MEN2B tumors are more 
aggressive, with an earlier onset and higher mortality.
MEN2 types carry approximately 100% risk for MTC and 
at 50% risk for PCC. FMTC tumors are less aggressive and, by 
definition, without incidence of other endocrine neoplasia. There 
is a strong correlation between the phenotype and genotype in the 
clinical subtypes of MEN2 with respect to age of onset and aggres-
siveness of MTC. These aspects are used to determine the time 
of prophylactic thyroidectomy and whether patients should be 
screened for PCC and hyperparathyroidism. In this way, positive 
results for a specific RET mutation can influence the management 
of an apparently sporadic MTC.
Pheochromocytomas in MEN2A and B are usually benign, 
bilateral in half of the patients, and can rarely be extra-adrenal. 
The malignancy affects <5% of PCCs in this syndrome (16, 17). 
Mutation in codons 618, 620, and 634 of RET is representative 
of MEN2A in approximately 80% of patients. A single missense 
mutation in codon 918 is found in nearly 90% of MEN2B cases. 
Based on this genotype and phenotype correlation, the American 
Thyroid association has proposed the classification of four risk-
categorized mutations and recommends the screening for PCC 
by the age of 20 years for MEN2A and by 8 years for MEN2B (18). 
One group has reported a high penetrance of PCCs, especially 
bilateral and large tumors, associated with a double C634/Y719F 
germ-line mutation in the RET protooncogene (19).
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von Hippel–Lindau Syndrome
Von Hippel–Lindau syndrome is an autosomal dominant disease 
associated with inactivating mutations in the VHL tumor sup-
pressor gene located on chromosome 3. This disease is character-
ized by a multiplicity of benign and malignant tumors, including 
retinal and central nervous system (CNS) hemangioblastomas, 
pancreatic islet cell tumors and pancreatic cysts, epididymal 
cystadenomas, endolymphatic sac tumors, clear-cell renal carci-
nomas and PCCs, and PGLs (20–23).
This syndrome is divided into type 1 or type 2 based on the 
absence or presence of PCC, respectively. The VHL type 2 is fur-
ther classified as 2A for patient with low risk of developing clear 
renal cell carcinoma, type 2B for patients with high risk of these 
tumors, and 2C for patients with only PCCs in the absence of 
the others classical tumors of the syndrome (23, 24). VHL muta-
tions result in unilateral or bilateral PCCs and rarely in PGLs. 
Approximately half of the cases are bilateral and benign tumors, 
with malignant phenotype present in <5% of the patients (10, 25). 
The mean age at diagnosis of these tumors is in the second decade, 
generally approximately 30 years, and the absence of signs and 
symptoms is frequent. PCCs and PGLs are the first manifestation 
in approximately 30–50% of the cases. Due to these aspects, it has 
been proposed that catecholamine screening should be started at 
approximately 5 years old, especially in patients with a positive 
familial history of PCCs (12, 26).
There are some correlations between the genotype and the 
phenotype in this syndrome. The VHL gene comprise three 
exons, and its mutations are distributed throughout the coding 
sequence; missense, nonsense, splice-site mutations, micro dele-
tions, and insertions are found in two-thirds of patients, while 
large deletions are described in only one-third of patients with 
this syndrome (20, 27). Deletions, nonsense, and frame shift 
mutations are regularly found in VHL type 1, whereas missense 
mutations are more common in VHL type 2. A majority of patients 
with PCC have missense mutations. Maher et al. (20) analyzed the 
genotype–phenotype correlations in 573 individuals with VHL 
disease and demonstrated that classifying missense substitutions 
according to their predicted effect on pVHL structure enhances 
the ability to predict pheochromocytoma risk. Although genetic 
screening has been able to identify mutations in the majority of 
patients with VHL disease, some patients (20%) without genetic 
diagnosis probably develop de novo mutations (28).
Neurofibromatosis Type 1
Neurofibromatosis type 1 (NF1) or Von Recklinghausens’s disease 
is an autosomal dominant syndrome characterized by café au lait 
macules, cutaneous or subcutaneous neurofibromas, skinfold 
freckling, and iris Linch nodules. These characteristics occur in an 
average of 90% of all NF1 adult patients, but the number of lesions 
is quite variable. Several other tumors, such as nerve glioma, 
dysplasia of the long bones, peripheral nerve sheath tumors, gas-
trointestinal stromal tumors (GIBT), rhabdomyosarcomas, breast 
cancer, and chronic myeloid leukemia, have also been described. 
Some patients can also present cognitive impairment (29, 30).
Pheochromocytomas are a rare finding in NF1, being identified 
in <6% of cases; however, they have a higher prevalence (13%) in 
autopsy series. The preferential mean age of presentation is in 
the fourth decade. A majority of these PCCs are unilateral and 
benign, while approximately 10% can be bilateral or malignant. 
The presence of PGLs is not common in NF1 (31, 32). Considering 
these aspects, the main features of PCCs in NF1 are very similar 
to those of sporadic PCCs.
NF1 is a tumor suppressor large gene with 60 exons located on 
chromosome 17 with described missense, nonsense, and splice-
site mutations, indels, and chromosomal rearrangements (33). 
These mutations are spread all over the gene without a hot spot, 
and the majority are located in the exons with variable penetrance 
and expression (32).
The NF1 protein, neurofibromin, is a GTPase that suppresses 
cell proliferation by inactivating RAS and inhibiting the RAS/
RAF/MAPK signaling pathways. When this gene is mutated, 
the cascade including PI3K and mTor is activated, subsequently 
resulting in uncontrolled cellular growth and differentiation (34). 
Some studies have suggested a possible novel potential NF1 geno-
type–phenotype correlation, especially with splice-site mutations 
associated with an increased tendency to develop neoplasms as 
CNS gliomas and malignant peripheral nerve sheath tumors (12). 
However, the diagnosis of the NF1 is established mainly based on 
the clinical aspects because it is difficult to genetically screen in 
the absence of hot spot mutations.
Familial PCC/PGLs
SDHx-Associated PCCs and PGLs
In the last decade, the genetics of hereditary PCC/PGLs has started 
to emerge with the description of germ-line mutations in the 
SDHx (SDH) genes related to this syndrome. The SDH complex 
is described as a heterotetrameric protein involved in the electron 
transport in the Kreb’s cycle and mitochondrial respiratory chain. 
This enzyme is composed of four subunits (SDHA, SDHB, SDHC, 
and SDHD) that catalyze the oxidation of succinate to fumarate. 
The catalytic subunits, SDHA and SHDB, are inserted in mito-
chondrial matrix, and they are affixed to the inner membrane 
by subunits SDHC and SDHD. The SDHx genes are supposed to 
work as classical tumors suppressors, as tumors frequently show 
loss of heterozygosity (LOH) of the non-mutated allele.
The relations between SDH and PCC/PGLs emerged in the 
2000s when germ-line SDHD mutations were associated to the 
occurrence of PCC/PGLs (35). SDHD is located on chromosome 
locus 11q23, has four exons, and is maternally imprinted (36, 37). 
The disease susceptibility occurs when the mutation is inherited 
from the father with rare exceptions.
SDHD mutations are linked to the development of familial 
PGLs and PCCs (PGL1), although they have been reported in 
apparently sporadic tumors; they are often associated with the 
risk of multiple tumors, especially head and neck PGLs (38, 39). 
PCC can occur usually unilateral (40). Malignancy associated 
with SDHD-derived PCC/PGL is quite rare.
The PGL2 syndrome is associated with SDHAF2 mutations, 
also known as SDH5. The SDHA mutation has been described with 
Leigh’s disease, a severe type of encephalopathy. The SDHA maps 
to chromosome 5p15, its products undergo post-translational 
modification by SDHAF2, and the gene of this protein has been 
implicated in development of hereditary head and neck PGLs (41, 
42). Mutations in SDHAF2 are considered rare; in a study with 
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443 patients with head and neck PGL evaluated, mutations on the 
SDHAF2 gene were negative.
Mutations in SDHC are implicated in PGL3 syndrome. The 
gene is located on chromosome 1q23.3 and presents six exons. 
A mutation in SDHC is less frequent when compared to SDHD 
mutations; it is usually associated with benign solitary head 
and neck PGLs. Also, extra-adrenal PGLs and PCCs have been 
described in this syndrome. Malignancy associated with the 
SDHC gene is extremely rare (43).
Mutation in SDHB is implicated in PGL 4 syndrome, charac-
terized mostly by abdominal, pelvic, and thoracic catecholamine-
secreting familial PGL. The SDHB gene is located on chromosome 
1p36.1, with eight exons. The risk of malignancy is great with 
this disease; less frequently, these mutations are found in PCCs 
or parasympathetic PGLs. The associated risk of malignancy is 
difficult to determine, especially because metastases can occur up 
to 20–30 years after primary tumors, and the applied definitions 
of malignancy vary between different studies (44).
Furthermore, SDHB mutations may result in susceptibility 
to other malignant tumors, such as renal cell carcinomas, papil-
lary thyroid tumors, neuroblastoma, or gastrointestinal stromal 
tumor (GIST). Average 20% of patients with SDHB mutation will 
present malignant PGLs, and more than 50% of the individu-
als with malignant PGLs will have a SDHB mutation (40, 44). 
Recently, mutations in this gene and in SDHD and SDHC were 
described in association with Carney–Stratakis syndrome, an 
autosomal dominant disorder characterized by PGLs and GIST, 
but they have not been found in other forms of the Carney triad, 
suggesting that other genetic alterations may be implicated in this 
syndrome (45).
More efforts are needed to define the risk of other cancers in 
association with these mutations in order to help clinicians better 
design a phenotype and genotype correlation in PCC\PGLs and 
understand the complexity of these diseases.
Carney Triad and Carney–Stratakis Syndrome
Carney triad is a syndrome of tumors involving at least five 
organs, the stomach, the lung, the paraganglionic system, the 
adrenal (cortex and medulla), and the esophagus. The stomach 
features GIST, the lung chondroma, the paraganglionic system 
paraganglioma, the adrenal adenoma and pheochromocytoma, 
and the esophagus leiomyoma (46).
The etiology of the Carney triad syndrome is unknown; no 
candidate gene has been discovered until now and the disease 
does not appear in a family pattern. The younger age and female 
predilection of affected individuals do implicate in a link with 
an inherited genetic defect; however, the screening of SDHA, 
SDHB, SDHC, and SDHD mutations has been always negative. 
The mutated genes, often associated to GIST (KIT and PDGFRA), 
are also not affected.
Differently, Carney–Stratakis syndrome is inherited in an 
autosomal-dominant manner that includes PGLs and GIST with-
out pulmonary chondromas (47). This disease affects equally men 
and women and the majority of patients present germ-line muta-
tions in SDHB, SDHC, or SDHD supporting another molecular 
mechanism linked to GIST besides KIT and PDGFRA mutations 
usually described (48).
The associated PCC and PGLs in these syndromes can be dif-
ferent. In Carney triad disease, the majority of patients present 
with PGLs, including sympathetic and parasympathetic tumors, 
with 28 years old of mean age presentation; 11% of the patients 
present metastasis (49). In Carney–Stratakis syndrome, the 
majority of patients have a sympathetic or parasympathetic PGLs, 
with a mean age of 33 years old; however, no malignant tumors 
were described (47).
New PCCs and PGLs Susceptibility Genes
Despite identification of multiple genetic causes of PGLs and 
PCCs in the last decade, around two-thirds of these tumors remain 
without molecular diagnosis, suggesting that other susceptibility 
genes could be implicated. Using a wide-genomic approach, 
PCC/PGLs were clustered in two major groups depending on 
their global transcription profiles. Cluster 1 includes VHL, SDHx, 
FH-mutated tumors and a part of the sporadic PCC/PGLs. This 
group was composed of tumors without clear mutation or sporadic 
tumors; they showed signatures of pseudo hypoxia, angiogenesis, 
and decreased oxidoreductase response. This profile links these 
tumors with hypoxia-inducible factor (HIF) role, and overexpres-
sion of HIF1α and 2α were found in this cluster.
A second group (cluster 2) covered PCCs with RET, NF1, 
KIF1Bβ, and undefined tumors enriched for kinase receptor 
signaling pathways, translation initiation, protein synthesis, and 
genes involved in neural/neuroendocrine identity (50–52). Novel 
genes, such as TMEM127, were also identified in this cluster 
(53). Also, deregulation of another pathway involving egl nine 
homologs was suggested (54).
KIF1β is a tumor suppressor gene necessary for neuronal 
apoptosis. It is located on chromosome 1 (55). Mutation in this 
gene was described in patients with PCC without other predis-
posing mutations. No specific phenotype has been identified 
yet; however, patients with KIF1β seem to be prone to PCC and 
neuroblastomas. Ganglioneuromas, leiomyosarcomas, and lung 
adenocarcinomas have also been reported (50).
In 2008, a germ-line mutation in EGLN1, also called PHD2, 
was reported in a patient with erythrocytosis and recurrent 
para-aortic PGL. EGLN1 is a member of EGLN prolyl hydroxy-
lase family that plays a major role regulating the HIF, which is 
involved in angiogenesis, erythropoiesis, cell metabolism, and 
proliferation. This gene was linked to familial erythrocytosis but 
not in association with tumors. A mutation analysis of 82 patients 
with inherited PCC did not detect mutations in EGLN1, EGLN2, 
or EGLN3, suggesting that mutations in these genes are not a 
frequent cause of inherited PCC (56).
TMEM127 was recently identified as a PCC/PGLs suscep-
tibility gene using linkage analysis and transcription profiling 
by microarray and copy number analysis of these tumors. It is 
possible that TMEM127, located on chromosome locus 2q.11.2, 
could be a tumor suppressor gene playing a role in cell signaling 
associated with kinase receptor signals and as a negative regulator 
of mTOR, which promotes cell growth and protein translation 
(53). The most common clinical presentation of the mutation 
carriers is quite similar to sporadic PCC patient, single adrenal 
tumor with mean age of 40 years (57, 58), although multiple head 
and neck PGLs and retroperitoneal PGLs have been described. 
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Unilateral and bilateral tumors have also been found, but malig-
nancy is rare.
MYC-associated factor X (MAX) is a transcription factor 
that was recently linked to PCC/PGL susceptibility. MAX is 
located on chromosome locus 14q23 and was associated with 
other cancers, such as neuroblastomas, acting as an oncogene 
or interacting with MYC family as a transcriptional suppressor 
(59, 60). Whole genome sequencing identified MAX germ-line 
mutations in familial cases of PCC without alterations in known 
genes. Comino-Mendez et al. studied 12 PCC patients with MAX 
mutations; three of the cases were unrelated individuals with 
hereditary PCC (59). The absence of MAX protein in the tumors 
and LOH of the wild-type allele in these tumors confirmed the 
tumor suppressor role of this gene in humans. Eight of these 
patients (67%) had bilateral PCCs, and 25% presented metastasis 
at diagnosis, suggesting that MAX mutation can be associated to 
multicentricity and malignant risk.
Genes and Sporadic PCC/PGLS
A problem that concerns clinicians is whether all sporadic PCCs 
should be screened for unsuspected germ-line mutations in genes 
associated with hereditary PGLs or PCCs. This aspect is not well 
clarified in the literature; the studies usually not include the analyses 
of all genes implicated in the familial forms. In a review by Jiménez 
et al., the authors provide a compilation of several studies, and the 
results suggest that 20% of patients with apparently sporadic PCCs 
have a germ-line mutation of one of the genes known to cause 
hereditary PCC/PGLs. When the authors excluded patients with 
bilateral or muticentric tumors with larger probability of familial 
disease, the amount was reduced to 17% (5.04% for VHL, 6.38% 
for PGL4, 3.72% for PGL1 e 1.55% for RET) (61).
In one study developed by Neumann et al., it was found that 24% 
of the patients with apparently non-syndromic pheochromocyto-
mas and no family history of the disease had mutations in VHL, 
RET, SDHD, and SDHB genes; these patients presented at a younger 
age (average of 24 years), and they had multiple tumors and 28% 
extra-adrenal tumors (62). Another study developed by the same 
group reinforced that up to 35% of patients with PCC/PGLs can be 
associated to an inherited mutation in these genes (32).
A Spanish group analyzed 135 apparently sporadic patients 
with a single tumor for the five susceptibility genes: VHL, RET, 
SDHB, SDHC, and SDHD. They found that 14% of the cases har-
bor germ-line mutations; a majority (98%) of them had tumors 
with younger onset, not more than 45 years old (63).
Demographic, clinical, and genetic evaluation was performed 
in a series of 71 patients with PCC/PGLs. Among 59 patients with 
apparently sporadic disease, unsuspected germ-line mutations 
occurred in 8 cases (13.6%). The authors did not find any dif-
ference between hereditary and sporadic disease concerning age, 
sex, and tumor size; bilateral and recurrent diseases were most 
common in hereditary cases (64).
Currently, the overall hereditary predisposition of PCCs is 
estimated to be approximately 20–35%. The high prevalence of 
unsuspected mutations indicates a demand for more extensive 
genetic tests for patients with these tumors (65). However, we 
have to be aware of the aspects that can influence the prevalence 
of the PCC/PGL mutations: tertiary care centers are more prone 
to evaluate patients with multiple and more complicated PCCs. 
Specific genetic disorders are more prevalent in some geographic 
regions, and major effort is being currently contributed to easier 
recognition of these syndromes. An Endocrine Society taskforce 
that compiled 31 studies including 5031 patients with apparently 
sporadic PCC/PGLs screened for numerous genes, and the task-
force reinforces this idea, as they found approximately 11–13% 
germ-line mutations in this population (66).
Somatic mutations in sporadic pheochromocytoma/paragan-
glioma has been identified in VHL, RET, SDHB, and SDHD but 
their frequency was reported to be low. The COMETE cohort 
has demonstrated the occurrence of somatic mutations in VHL 
and RET genes in 14% of sporadic pheochromocytoma/paragan-
glioma, one germ-line, and three somatic mutations in the MAX 
were described by the same cohort (67, 68). Burnichon et al. have 
found that 41% (25/61) of the sporadic tumors in their population 
harbor an inactivating somatic mutation in the NF1 gene associ-
ated with loss of the wild-type allele in 84% (21/25) of cases (69). 
These findings reinforce that somatic mutation in sporadic PCC/
PGLs can be more often than previously considered.
Genetic Screening Strategy in Patients 
with PCC and PGL
The American Society of Clinical Oncology suggests that all 
patients with PCC and PGLs should be submitted to genetic 
screening. It is currently accepted from the literature that approxi-
mately 30–35% of the PCC/PGLs are associated with germ-line 
mutations in one of the genes described above (70).
Molecular analysis has revealed that a significant number of 
PCC/PGLs, previously considered as sporadic tumors, have a 
genetic predisposition. However, in the last decade, several new 
genes were implicated in this disease, and we have considered 
the cost and availability of genetic tests before using them as 
diagnostic tools in PCC/PGLs.
Some characteristics, including personal or family history of 
PCC/PGLs, are very important. A detailed and medical family 
history and sometimes a specialized genetic consultation provide 
the potential consequences of genetic testing. In the absence of 
any family history, the description of sudden death without other 
cardiovascular disease should call attention. Clinical manifesta-
tions in the patient or other family members can point to a par-
ticular hereditary condition. For example, subtle retinal vascular 
lesions can indicate the possibility of VHL disease.
Generally, hereditary tumors occur at a younger age than the spo-
radic ones; age of diagnostics younger than 40 years is an  important 
factor to call for a genetic test. An interesting study suggests that 
patients with epinephrine-producing tumors (mean age 50 years) 
were diagnosed 11 years later than those with tumors lacking appre-
ciable epinephrine production (mean age 42  years). This finding 
reinforces that the cut-off age for genetic screening could consider 
tumor catecholamine phenotypes (71). However, finding nearly 
36% germ-line mutations in children make these tests necessary in 
this group of patients (72). Presence of head and neck PGLs, bilat-
eral or multifocal tumors, and the presence of malignancy should 
raise the suspicion of a possible hereditary abnormality (73, 74).
TABLe 1 | Clinical and genetic features of the most frequent pheochromocytomas and paragangliomas-related syndromes.
Gene Loci Protein function Syndrome Clinical manifestations or associated 
TU
inheritance Primary location Malignacy 
rate
RET 10q11.2 Transmembrane 
tyrosine kinase
MEN2A MTC, Hyperparathyroidism, cutaneous 
lichen amyloidosis
AD PCC (single ou bilateral) <5%
MEN2B MTC, mucosal neuromas, marfanoid 
habitus
VHL 3p25–26 Ubiquitin ligase 3E 
activity
VHL Hemangioblastomas, clear-cell renal cell 
carcinomas; endolymphatic sac tumors, 
cystadenomas; pancreatic islet cell tumor
AD PCC (>bilateral) <5%
NF1 17q11.2 GTPase NF1 Café au lait macules, neurofibromas, 
iris Linch nodules, optic nerve gliomas, 
dysplasia of the long bones, astrocytomas, 
soft tissue sarcomas, CML, childhood 
learning disabilities, seizures
AD PCC (>single) 12%
SDHD 11q23.1 Complex II anchoring 
subunit
PGL1 Papillary thyroid cancer; GIST AD; PI HNPGL/MPGL <5%
SDHAF2 11q13.1 Cofactor for complex II PGL2 GIST AD; PI HNPGL/MPGL Low
SDHC 1q23.3 Complex II-anchoring 
subunit
PGL3 GIST AD HNPGL > SPCC = TAPGL =  
MPGL
Low
SDHB 1p36.1 Complex II catalytic 
subunit
PGL4 Renal cell carcinomas; GIST, thyroid 
tumors, neuroblastomas
AD TAPGL > HNPGL = SPGL =  
MPGL < SPCC
30–70%
SDHA 5p15 Complex II catalytic 
subunit
AD TAPGL/HNPGL Low
TMEM127 2q11.2 Transmembrane 
protein
AD SPCC > BPCC > TAPGL =  
HNPGL = MPGL
Low
MAX 14q23–3 BHL HLZ transcription 
factor
ADPI SPCC = BPCC > TAPGL 10%
AD, autosomal dominant; PI, paternal inheritance; TAPGL, thoracic or abdominal PGL; HNPGL, head and neck PGL; SPCC/PGL, single PCC/PGL; BPC/PGL, bilateral PCC/PGL; 
MPGL, multiplal PGL.
FiGURe 2 | Algorithm proposed for genetic testing for pheochromocytomas and paragangliomas patients. The gene described might be considered for 
testing in this order. Mutations in TMEM127, MAX, HIF2A, and SDHAF2 are quite rare and should be contemplated in patients with negative test for the other genes.
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For family diseases, such as MEN2A/B, NF1, and VHL, a phe-
notype suspicion, because they are commonly associated to other 
tumors, helps to direct to genetic studies. The presence of heman-
gioblastomas calls attention for VHL disease, as the association 
of medullary thyroid carcinoma for MEN2. MEN2-associated 
tumors always produce epinephrine and can be uni- or bilateral, 
but malignant disease and extra-adrenal tumors are rare in this 
syndrome. PCCs in VHL always secrete NE and can be extra-
adrenal. The biochemical profile, as shown in Figure 2, is very rel-
evant to help and guide the genetic test. Diagnosis of NF1 is based 
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on clinical features, and genetic testing is usually not required, 
because NF1 is a large gene, costly, and difficult to screen.
Adrenal (unilateral or bilateral) PCCs are frequently associ-
ated with VHL and RET, while extra-adrenal sympathetic PGLs 
(abdominal or thoracic) are usually caused by SDHB, SDHD, 
and VHL mutations (75–77). Head and neck tumors are mainly 
caused by SDH mutations, especially SDHD and B, and less 
often by VHL and SDHC (25, 40). SDHC mutations have been 
described exclusively in patients with parasympathetic PGLs 
and quite rare in association with sympathetic PCC/PGLs (43). 
Tests for this gene are only indicated in these cases. Genetic test 
for SDHB is indicated in all patients with malignant PGL or 
PCC, and up of 50% of these tumors have an SDHB mutation. 
Elevation of dopamine with NE has been found in these tumors. 
Unlike classical syndromes, only 10% of the SDHB patients have 
a positive family history.
TMEM127 is customarily associated with benign PCC but not 
with PGL. Ordinarily, these tumors occur in old age, mimicking 
a truly sporadic PCC (57, 64).
Routine screening for germ-line mutations in patients with 
PCC/PGLs is costly and time consuming. Although some algo-
rithms have been proposed, no routine guideline is available (73). 
For these reasons, the genetic screening directions are mostly 
based on clinical expertise, including clinical signs, the biochemi-
cal phenotype, and symptoms (Figure 2; Table 1). Understanding 
the genetic profile of these tumors and considering the patient’s 
risk for developing multifocal lesions, malignant PCC/PGLs, and 
other malignancies provide a very important tool for following 
patients with this condition. Regarding these aspects, we suggest 
to screening all patients with multiple tumors, especially with 
extra-adrenal and head and neck tumors. Age is an important 
factor; nevertheless, some studies have demonstrated that the 
age range can be quite wide, even for familial forms. The genes 
might be screened according to clinical presentation; then cost 
and effective analyses, screening of SDHB and VHL should be 
considered. The most important clinical aspects related to differ-
ent genes are provided in Table 1. Head and neck PGLs should be 
first screened for SDHD and SDHC mutations.
Currently, it is recommended that if a mutation is found, it 
is not necessary to search for additional genomic alterations; 
however, with the description of new genes, we have to be 
aware of new possibilities. Identification of a gene mutation in 
patients with PCC/PGLs results in precocious diagnosis and 
better surveillance, resulting in better prognosis. In specific 
cases, RET screening and genotype and phenotype correla-
tion permits prophylactic surgery for an aggressive tumor. 
Nevertheless, further clinical studies are indispensable to 
better correlate genotype and phenotype features with the new 
genes.
Conclusion
To guide better screening strategy and optimize therapeutic 
options, the knowledge of PCC/PGL-implicated syndromes and 
genes is incredibly important. This review summarizes the main 
syndromes and the gene associated with these diseases. Further 
studies are needed for wider genotype to phenotype correlations, 
especially for new genes and pathways recently described for 
these tumors.
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